Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Microenvironmental CTHRC1 protein promotes colorectal cancer tumor growth

A new research paper was published in Volume 17 of Oncotarget on May 20, 2026, titled "Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer."

2 Jun 2026

Cross-reactive T cells target measles and dangerous Nipah viruses

T cells are some of the immune system's most important warriors. They can stop tumor growth and even fight off severe infections.

2 Jun 2026

New discovery provides insights into how seasonal influenza viruses infect people

Scientists investigating how influenza viruses replicate within cells "accidentally" discovered that different flu viruses use distinct strategies to infiltrate cells in the first place.

2 Jun 2026

How dysregulated collagen IV homeostasis causes cerebral microbleeds

Millions of older adults have tiny brain hemorrhages called cerebral microbleeds, which are strongly associated with dementia, cognitive decline, and stroke.

2 Jun 2026

Tissue rigidity actively regulates cell polarity and embryonic development

Embryonic development is one of the most dynamic biological processes in nature. Cells and tissues organise and reorganise themselves following incredibly precise patterns, while remaining flexible and robust.

2 Jun 2026

Introducing Evosep Proteomics to standardize and scale proteomics for research and drug development

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

From Evosep 2 Jun 2026

Cellular reprogramming helps outsmart progressive Alzheimers disease

A team led by researcher José Vicente Sánchez Mut at the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and the Miguel Hernández University of Elche (UMH), together with researcher Johannes Gräff at the École Polytechnique Fédérale de Lausanne (EPFL), has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their protective function against Alzheimer's disease.

2 Jun 2026

New blood test tracks real time gene expression inside living brain tissue

Cell function is determined by how DNA is expressed into proteins. That process includes two main steps - transcription, when messenger RNA (mRNA) makes copies of active genes, and translation, when mRNA guides protein assembly.

2 Jun 2026

Genetic testing finds breast cancer risks that standard screening models miss

Population-based pathogenic variant testing identified breast cancer susceptibility gene carriers who would often be missed by clinical risk models, even when polygenic risk scores were added. In the WISDOM Study analysis, fewer than 1% of high-penetrance variant carriers would have received the same high-risk screening recommendation using clinical plus polygenic risk alone.

1 Jun 2026

Study shows how HIV leads to chronic pain

Over half of the people carrying HIV experience chronic pain at some point, which is difficult to treat. In a new JNeurosci paper, Hui-Lin Pan, from The University of Texas MD Anderson Cancer Center, and colleagues used mice to explore how HIV leads to chronic pain.

1 Jun 2026

Targeting microRNA pathway helps overcome cancer immunotherapy resistance

Immune checkpoint therapy, a type of cancer immunotherapy that helps the immune system recognize and attack tumors, has transformed cancer treatment.

1 Jun 2026

Physical activity protects heart health regardless of weight loss

With obesity now affecting more than 40% of U.S. adults and fueling rising rates of heart disease, a new scientific statement from the American Heart Association calls for a comprehensive treatment approach that puts physical activity front and center.

1 Jun 2026

Vaccine and drug combination cuts melanoma recurrence by half

The combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence by 49 percent, a new study shows.

1 Jun 2026

Understanding mitochondrial biology in alcohol-associated liver disease and cancer

For decades, giant mitochondria-known as megamitochondria-have been recognized in liver biopsies from patients with alcohol-associated liver disease (ALD).

1 Jun 2026

Global policy gaps slow biosimilar adoption and access

Nine out of 10 prescriptions are filled by generic drugs - FDA-approved carbon copies of brand-name drugs with expired patents.

1 Jun 2026

New PET imaging tracks tumor progression and cardiac inflammation during cancer therapy

A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses during cancer treatment.

1 Jun 2026

PSMA PET detects high-risk prostate cancer bone metastases

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients a critical indicator of a patient's long-term survival.

1 Jun 2026

Justicia carnea extract alleviates oxidative stress in pancreatitis

Chronic pancreatitis is an inflammatory disease and is difficult to manage despite advancements in medical science.

1 Jun 2026

New T-cell engager therapy shows effectiveness in advanced solid tumors

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.

1 Jun 2026

Daraxonrasib significantly extends survival in metastatic pancreatic cancer

At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

31 May 2026